Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRAT | P43155 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 4/20 | 0.38 |
| ▸ | CPT1A | P50416 | 4/20 | 0.38 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680825 | 1.00 | CRAT (0.44) | CRATALDH1A1CPT2CPT1ACPT1B | |
| SCHEMBL14823034 | 0.92 | ALDH1A1 (0.40) | CRATALDH1A1TAS1R3TAS1R1HDAC3 | |
| SCHEMBL3687169 | 0.83 | CRAT (0.49) | CRATMMP2 | |
| SCHEMBL3687172 | 0.83 | CRAT (0.49) | CRATMMP2 | |
| SCHEMBL13410016 | 0.80 | IKBKB (0.38) | CRATALDH1A1TAS1R3TAS1R1KMT2A | |
| SCHEMBL3680337 | 0.80 | ACACB (0.46) | CRATCPT2CPT1ACPT1B | |
| SCHEMBL3680338 | 0.80 | ACACB (0.46) | CRATCPT2CPT1ACPT1B | |
| SCHEMBL3689207 | 0.78 | CRAT (0.44) | CRATCPT2CPT1ACPT1BTAS1R3 | |
| SCHEMBL3689202 | 0.78 | CRAT (0.44) | CRATCPT2CPT1ACPT1BTAS1R3 | |
| SCHEMBL13410015 | 0.78 | MMP2 (0.44) | ALDH1A1CPT2CPT1ACPT1BMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CRAT 5/4885ALDH1A1 236/4885CPT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.